Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach

Journal of Colloid and Interface Science

Volumn 462, Issue , 2016, Pages 368-374

  Soo, Ernest ^a   Thakur, Sachin ^a   Qu, Zhi ^a   Jambhrunkar, Siddharth ^a   Parekh, Harendra S ^a   Popat, Amirali ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anticancer; Colorectal cancer; Cyclodextrin; Liposome; Nanoparticles; Resveratrol

Indexed keywords

CELL CULTURE; CYCLODEXTRINS; CYTOTOXICITY; DISEASES; LIPOSOMES; NANOPARTICLES; PARTICLE SIZE;

ANTICANCER; ANTICANCER POTENTIALS; CHEMOTHERAPEUTIC AGENTS; COLORECTAL CANCER; CYCLODEXTRIN COMPLEXES; LIPOSOMAL FORMULATION; POLYDISPERSITY INDICES; POLYMERIC NANOPARTICLES;

RESVERATROL;

CYCLODEXTRIN; DRUG CARRIER; RESVERATROL; ANTINEOPLASTIC AGENT; NANOPARTICLE; STILBENE DERIVATIVE;

ARTICLE; COLON CANCER; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; LIPOPHILICITY; LIPOSOMAL DELIVERY; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HT 29 CELL LINE; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HT29 CELLS; HUMANS; NANOPARTICLES; PARTICLE SIZE; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES;

EID: 84945242875     PISSN: 00219797     EISSN: 10957103     Source Type: Journal    
DOI: 10.1016/j.jcis.2015.10.022     Document Type: Article

References (48)

1. Xu R., et al. Recent advances in the treatment of colon cancer. Histol. Histopathol. 2006, 21(8):867-872.
2. Lao V.V., Grady W.M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 2011, 8(12):686-700.
3. Chan A.T., Giovannucci E.L. Primary prevention of colorectal cancer. Gastroenterology 2010, 138(6):2029-2043. e10.
4. Tarraga Lopez P.J., Albero J.S., Rodriguez-Montes J.A. Primary and secondary prevention of colorectal cancer. Clin. Med. Insights Gastroenterol. 2014, 7:33-46.
5. Amri A., et al. Administration of resveratrol: what formulation solutions to bioavailability limitations?. J. Control. Release 2012, 158(2):182-193.
6. Neves A.R., et al. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug delivery, and membrane interactions. Curr. Med. Chem. 2012, 19(11):1663-1681.
7. Mattarei A., et al. Acetal derivatives as prodrugs of resveratrol. Mol. Pharm. 2013, 10(7):2781-2792.
8. Trela B.C., Waterhouse A.L. Resveratrol: isomeric molar absorptivities and stabilities. J. Agri. Food Chem. 1996, 44(5):1253-1257.
9. Miki H., et al. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int. J. Oncol. 2012, 40(4):1020-1028.
10. Summerlin N., et al. Resveratrol nanoformulations: challenges and opportunities. Int. J. Pharm. 2015, 479(2):282-290.
11. Popat A., et al. Programmable drug release using bioresponsive mesoporous silica nanoparticles for site-specific oral drug delivery. Chem. Commun. 2014, 50(42):5547-5550.
12. Jambhrunkar S., et al. Modulating in vitro release and solubility of griseofulvin using functionalized mesoporous silica nanoparticles. J. Colloid Interface Sci. 2014, 434:218-225.
13. Jambhrunkar S., et al. Mesoporous silica nanoparticles enhance the cytotoxicity of curcumin. RSC Adv. 2014, 4(2):709-712.
14. Pinho E., et al. Cyclodextrins as encapsulation agents for plant bioactive compounds. Carbohydr. Polym. 2014, 101:121-135.
15. Tiwari G., Tiwari R., Rai A.K. Cyclodextrins in delivery systems: applications. J. Pharm. Bioallied. Sci. 2010, 2(2):72-79.
16. Thakur S.S., et al. Solubilization of poorly soluble drugs. Computational Pharmaceutics 2015, 31-51. John Wiley & Sons, Ltd.
17. Das S., et al. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm. Res. 2008, 25(11):2593-2600.
18. Chen J., et al. Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs. Expert Opin. Drug Deliv. 2014, 11(4):565-577.
19. Popat A., et al. Curcumin-cyclodextrin encapsulated chitosan nanoconjugates with enhanced solubility and cell cytotoxicity. Colloids Surf. B Biointerf. 2014, 117:520-527.
20. Wang S., et al. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J. Nutr. Biochem. 2014, 25(4):363-376.
21. Coimbra M., et al. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int. J. Pharm. 2011, 416(2):433-442.
22. Lim H.J., et al. Polymer-associated liposomes as a novel delivery system for cyclodextrin-bound drugs. J. Colloid Interface Sci. 2008, 320(2):460-468.
23. Dhule S.S., et al. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomed. Nanotechnol. Biol. Med. 2012, 8(4):440-451.
24. McCormack B., Gregoriadis G. Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery. J. Drug Target. 1994, 2(5):449-454.
25. Torchilin V.P., Weissig V. Liposomes: A Practical Approach 2003, vol. 264:396. Oxford University Press, Oxford. second ed.
26. Mignet N., et al. Development of a liposomal formulation of the natural flavonoid fisetin. Int. J. Pharm. 2012, 423(1):69-76.
27. Seguin J., et al. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int. J. Pharm. 2013, 444(1-2):146-154.
28. Isailovic B.D., et al. Resveratrol loaded liposomes produced by different techniques. Innovative Food Sci. Emerg. Technol. 2013, 19:181-189.
29. Budai M., et al. Studies on molecular interactions between nalidixic acid and liposomes. Int. J. Pharm. 2004, 279(1-2):67-79.
30. Mozafari M.R., et al. Encapsulation of food ingredients using nanoliposome technology. Int. J. Food Prop. 2008, 11(4):833-844.
31. Hobbs S.K., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95(8):4607-4612.
32. Vanaja K., et al. Liposomes as carriers of the lipid soluble antioxidant resveratrol: evaluation of emelioration of oxidative stress by additional antioxidant vitamin. Life Sci. 2013, 93(24):917-923.
33. Maestrelli F., et al. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int. J. Pharm. 2006, 312(1-2):53-60.
34. Mendonca E.A., et al. Enhanced antiproliferative activity of the new anticancer candidate LPSF/AC04 in cyclodextrin inclusion complexes encapsulated into liposomes. AAPS PharmSciTech 2012, 13(4):1355-1366.
35. Bonechi C., et al. Using liposomes as carriers for polyphenolic compounds: the case of trans-resveratrol. PLoS One 2012, 7(8):1-11.
36. Sadovoy V., et al. An examination of chemical composition and molecular properties of grape berry skin flavonoids. Food Nutr. Sci. 2011, 2(10):1121-1127.
37. Nii T., Ishii F. Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int. J. Pharm. 2005, 298(1):198-205.
38. Selvaraj S., et al. Dose-dependent interaction of trans-resveratrol with biomembranes: effects on antioxidant property. J. Med. Chem. 2013, 56(3):970-981.
39. Silva F., et al. Strategies to improve the solubility and stability of stilbene antioxidants: a comparative study between cyclodextrins and bile acids. Food Chem. 2014, 145:115-125.
40. Agashe H., et al. Liposome-encapsulated EF24-HPbetaCD inclusion complex: a preformulation study and biodistribution in a rat model. J. Nanopart. Res. 2011, 13(6):2609-2623.
41. Kauscher U., et al. Incorporation of amphiphilic cyclodextrins into liposomes as artificial receptor units. Langmuir 2013, 29(24):7377-7383.
42. Fatouros D.G., Hatzidimitriou K., Antimisiaris S.G. Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release. Eur. J. Pharm. Sci. 2001, 13(3):287-296.
43. Detoni C.B., et al. Photostability and skin penetration of different E-resveratrol-loaded supramolecular structures. Photochem. Photobiol. 2012, 88(4):913-921.
44. Sur S., et al. Remote loading of preencapsulated drugs into stealth liposomes. Proc. Natl. Acad. Sci. 2014, 111(6):2283-2288.
45. Maestrelli F., et al. Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery. Int. J. Pharm. 2005, 298(1):55-67.
46. Chen H., et al. Preparation, characterization and pharmacokinetics of liposomes-encapsulated cyclodextrins inclusion complexes for hydrophobic drugs. Drug Deliv. 2007, 14(4):201-208.
47. Mignet N., Seguin J., Chabot G.G. Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics 2013, 5(3):457-471.
48. Morris C., et al. Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion 2014, 54(10):2514-2522.